citalopram has been researched along with Esophageal Diseases in 2 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Esophageal Diseases: Pathological processes in the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Aim To evaluate the acute effect of citalopram on oesophageal hypersensitivity." | 9.12 | Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. ( Broekaert, D; Fischler, B; Janssens, J; Sifrim, D; Tack, J, 2006) |
| " Aim To evaluate the acute effect of citalopram on oesophageal hypersensitivity." | 5.12 | Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. ( Broekaert, D; Fischler, B; Janssens, J; Sifrim, D; Tack, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rykova, SM | 1 |
| Pogromov, AP | 1 |
| Diukova, GM | 1 |
| Veĭn, AM | 1 |
| Broekaert, D | 1 |
| Fischler, B | 1 |
| Sifrim, D | 1 |
| Janssens, J | 1 |
| Tack, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788] | Phase 2/Phase 3 | 144 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for citalopram and Esophageal Diseases
| Article | Year |
|---|---|
Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study.
Topics: Adult; Citalopram; Double-Blind Method; Epidemiologic Methods; Esophageal Diseases; Female; Humans; | 2006 |
1 other study available for citalopram and Esophageal Diseases
| Article | Year |
|---|---|
[Psychophysiologic disorders in patients with functional disorders of upper sections of the gastrointestinal tract and with gastroesophageal reflux disease].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Esophageal Diseases; Gastroesophageal Reflux; | 2003 |